Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Medpace Holdings, Inc. (MEDP), a provider of clinical research-based drug and medical device development services, was a top contributor during the third quarter. Medpace reported its...
— Spyglass Capital Management
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Medpace Holdings, Inc.
Medpace is a global clinical contract research organization featuring a robust balance sheet and strong cash generation. While near-term growth...
Our investments in drug development companies like Charles River Labs (CRL) and Medpace Holdings (MEDP) pulled back, driven by AI disruption fears.
Medpace continues to outperform expectations by winning business awards and expanding free cash flow despite biotech funding noise. A debt-free balance...
More institutional theses from Spyglass Capital Management
Forgent Power Solutions, a recent IPO specializing in electrical distribution equipment, is well-positioned to benefit from a structural surge in electricity demand driven by AI, reshoring, and electrification. Having expanded capacity...
Despite delivering its 60th straight quarter of double-digit revenue growth, CoStar's stock fell due to softer net new bookings. The manager remains...
Added in April, QXO fell after announcing its acquisition of TopBuild due to market concerns over leverage and integration. However, the manager...